Harvard Bioscience (HBIO) Stock Forecast, Price Target & Predictions
HBIO Stock Forecast
Harvard Bioscience stock forecast is as follows: an average price target of $7.00 (represents a 205.68% upside from HBIO’s last price of $2.29) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
HBIO Price Target
The average price target for Harvard Bioscience (HBIO) is $7.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 205.68% upside from HBIO's last price of $2.29.
HBIO Analyst Ratings
According to 1 Wall Street analysts, Harvard Bioscience's rating consensus is 'Buy'. The analyst rating breakdown for HBIO stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Harvard Bioscience Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Paul Knight | KeyBanc | $7.00 | $3.12 | 124.36% | 205.68% |
The latest Harvard Bioscience stock forecast, released on Aug 08, 2024 by Paul Knight from KeyBanc, set a price target of $7.00, which represents a 124.36% increase from the stock price at the time of the forecast ($3.12), and a 205.68% increase from HBIO last price ($2.29).
Harvard Bioscience Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $7.00 |
| Last Closing Price | $2.29 | $2.29 | $2.29 |
| Upside/Downside | -100.00% | -100.00% | 205.68% |
In the current month, the average price target of Harvard Bioscience stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Harvard Bioscience's last price of $2.29. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | Benchmark | Speculative Buy | Speculative Buy | Hold |
| Aug 08, 2024 | KeyBanc | Overweight | Overweight | Hold |
| Mar 10, 2023 | Benchmark | - | Buy | Upgrade |
Harvard Bioscience's last stock rating was published by Benchmark on Aug 09, 2024. The company gave HBIO a "Speculative Buy" rating, the same as its previous rate.
Harvard Bioscience Financial Forecast
Harvard Bioscience Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $28.15M | $25.36M | $28.76M | $29.98M | $28.43M | $26.92M | $29.21M | $28.78M | $33.05M | $29.66M | $29.20M | $26.99M | $30.98M | $24.04M | $23.31M | $23.77M | $30.97M | $27.42M | $29.58M | $28.20M | $26.76M | $24.16M |
| Avg Forecast | $26.35M | $24.40M | $24.15M | $22.95M | $24.15M | $23.70M | $26.40M | $25.80M | $29.10M | $28.02M | $29.50M | $28.83M | $30.33M | $28.87M | $30.49M | $28.77M | $32.96M | $27.91M | $27.67M | $25.73M | $30.98M | $24.05M | $22.20M | $27.87M | $31.80M | $28.75M | $29.00M | $28.38M | $26.76M | $9.04M |
| High Forecast | $29.81M | $27.61M | $27.32M | $24.00M | $29.09M | $26.81M | $29.87M | $29.19M | $32.92M | $28.02M | $33.38M | $32.62M | $34.32M | $28.87M | $30.49M | $28.77M | $32.96M | $27.91M | $27.67M | $25.73M | $30.98M | $24.05M | $22.20M | $27.87M | $31.80M | $28.75M | $29.00M | $28.38M | $32.11M | $10.85M |
| Low Forecast | $23.63M | $21.88M | $21.66M | $21.90M | $20.47M | $21.25M | $23.67M | $23.13M | $26.09M | $28.02M | $26.45M | $25.85M | $27.20M | $28.87M | $30.49M | $28.77M | $32.96M | $27.91M | $27.67M | $25.73M | $30.98M | $24.05M | $22.20M | $27.87M | $31.80M | $28.75M | $29.00M | $28.38M | $21.41M | $7.24M |
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | 0.97% | 0.91% | 0.97% | 1.04% | 0.94% | 0.93% | 0.96% | 1.00% | 1.00% | 1.06% | 1.06% | 1.05% | 1.00% | 1.00% | 1.05% | 0.85% | 0.97% | 0.95% | 1.02% | 0.99% | 1.00% | 2.67% |
Harvard Bioscience's average Quarter revenue forecast for Mar 24 based on 1 analysts is $25.80M, with a low forecast of $23.13M, and a high forecast of $29.19M. HBIO's average Quarter revenue forecast represents a -8.36% decrease compared to the company's last Quarter revenue of $28.15M (Dec 23).
Harvard Bioscience EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | $-11.20M | $-933.00K | $1.81M | $3.14M | $1.17M | $-2.91M | $886.00K | $405.00K | $752.00K | $2.30M | $1.66M | $1.64M | $2.47M | $1.64M | $2.32M | $-1.25M | $3.33M | $612.00K | $2.12M | $1.58M | $-914.00K | $33.00K |
| Avg Forecast | $1.61M | $1.50M | $1.48M | $1.41M | $1.48M | $1.45M | $1.62M | $-6.95M | $1.78M | $1.72M | $1.81M | $-6.32M | $4.07M | $1.42M | $1.50M | $-5.74M | $1.63M | $1.38M | $1.37M | $1.29M | $1.53M | $1.19M | $1.10M | $-2.63M | $1.57M | $1.42M | $1.43M | $2.11M | $-914.00K | $36.30K |
| High Forecast | $1.83M | $1.69M | $1.67M | $1.47M | $1.78M | $1.64M | $1.83M | $-5.56M | $2.02M | $1.72M | $2.05M | $-5.05M | $4.88M | $1.42M | $1.50M | $-4.59M | $1.63M | $1.38M | $1.37M | $1.55M | $1.53M | $1.19M | $1.10M | $-2.10M | $1.57M | $1.42M | $1.43M | $2.53M | $-731.20K | $43.56K |
| Low Forecast | $1.45M | $1.34M | $1.33M | $1.34M | $1.25M | $1.30M | $1.45M | $-8.34M | $1.60M | $1.72M | $1.62M | $-7.58M | $3.25M | $1.42M | $1.50M | $-6.89M | $1.63M | $1.38M | $1.37M | $1.03M | $1.53M | $1.19M | $1.10M | $-3.15M | $1.57M | $1.42M | $1.43M | $1.69M | $-1.10M | $29.04K |
| Surprise % | - | - | - | - | - | - | - | - | -6.28% | -0.54% | 1.00% | -0.50% | 0.29% | -2.05% | 0.59% | -0.07% | 0.46% | 1.67% | 1.21% | 1.27% | 1.61% | 1.38% | 2.12% | 0.48% | 2.12% | 0.43% | 1.48% | 0.75% | 1.00% | 0.91% |
1 analysts predict HBIO's average Quarter EBITDA for Sep 23 to be $1.72M, with a high of $1.72M and a low of $1.72M. This is -5.29% lower than Harvard Bioscience's previous annual EBITDA (Jun 23) of $1.81M.
Harvard Bioscience Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 18 |
| Net Income | - | - | - | - | - | - | - | - | $-1.82M | $-1.24M | $-980.00K | $622.00K | $-1.67M | $-3.40M | $2.44M | $-6.88M | $961.00K | $-170.00K | $-410.00K | $-669.00K | $-615.00K | $-1.10M | $-1.58M | $-4.52M | $550.00K | $-2.62M | $-247.00K | $-2.37M | $-4.06M | $-1.07M |
| Avg Forecast | $1.96M | $654.21K | $1.09M | $218.07K | $1.96M | $654.21K | $2.18M | $-9.99M | $2.18M | $1.74M | $2.62M | $-9.08M | $672.22K | $2.90M | $2.61M | $-8.26M | $4.35M | $2.17M | $2.17M | $-527.09K | $3.48M | $1.52M | $-434.86K | $-9.48M | $3.77M | $2.61M | $1.74M | $-3.16M | $-4.06M | $-1.17M |
| High Forecast | $2.30M | $765.96K | $1.28M | $255.32K | $2.30M | $765.96K | $2.55M | $-7.99M | $2.55M | $2.04M | $3.06M | $-7.27M | $806.67K | $2.90M | $2.61M | $-6.60M | $4.35M | $2.17M | $2.17M | $-421.67K | $3.48M | $1.52M | $-434.86K | $-7.59M | $3.77M | $2.61M | $1.74M | $-2.53M | $-3.25M | $-938.08K |
| Low Forecast | $1.70M | $566.35K | $943.91K | $188.78K | $1.70M | $566.35K | $1.89M | $-11.99M | $1.89M | $1.51M | $2.27M | $-10.90M | $537.78K | $2.90M | $2.61M | $-9.91M | $4.35M | $2.17M | $2.17M | $-632.51K | $3.48M | $1.52M | $-434.86K | $-11.38M | $3.77M | $2.61M | $1.74M | $-3.79M | $-4.88M | $-1.41M |
| Surprise % | - | - | - | - | - | - | - | - | -0.83% | -0.71% | -0.37% | -0.07% | -2.48% | -1.17% | 0.93% | 0.83% | 0.22% | -0.08% | -0.19% | 1.27% | -0.18% | -0.72% | 3.64% | 0.48% | 0.15% | -1.00% | -0.14% | 0.75% | 1.00% | 0.91% |
Harvard Bioscience's average Quarter net income forecast for Jun 23 is $2.62M, with a range of $2.27M to $3.06M. HBIO's average Quarter net income forecast represents a 320.71% increase compared to the company's last Quarter net income of $622.00K (Mar 23).
Harvard Bioscience SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 18 |
| SG&A | - | - | - | - | - | - | - | - | $11.51M | $11.54M | $11.53M | $12.31M | $11.81M | $12.14M | $12.57M | $13.01M | $13.46M | $11.64M | $12.13M | $11.72M | $11.15M | $9.99M | $9.95M | $12.34M | $11.44M | $11.90M | $10.58M | $11.96M | $11.03M | $10.25M |
| Avg Forecast | $11.00M | $10.19M | $10.08M | $9.58M | $10.08M | $9.89M | $11.02M | $18.89M | $12.15M | $11.70M | $12.31M | $17.18M | $13.98M | $12.05M | $12.73M | $15.61M | $13.76M | $11.65M | $11.55M | $9.23M | $12.93M | $10.04M | $9.27M | $25.91M | $13.27M | $12.00M | $12.11M | $15.94M | $11.03M | $3.78M |
| High Forecast | $12.45M | $11.52M | $11.41M | $10.02M | $12.14M | $11.19M | $12.47M | $22.67M | $13.74M | $11.70M | $13.93M | $20.61M | $16.78M | $12.05M | $12.73M | $18.74M | $13.76M | $11.65M | $11.55M | $11.08M | $12.93M | $10.04M | $9.27M | $31.09M | $13.27M | $12.00M | $12.11M | $19.13M | $13.24M | $4.53M |
| Low Forecast | $9.86M | $9.13M | $9.04M | $9.14M | $8.54M | $8.87M | $9.88M | $15.11M | $10.89M | $11.70M | $11.04M | $13.74M | $11.18M | $12.05M | $12.73M | $12.49M | $13.76M | $11.65M | $11.55M | $7.39M | $12.93M | $10.04M | $9.27M | $20.73M | $13.27M | $12.00M | $12.11M | $12.75M | $8.82M | $3.02M |
| Surprise % | - | - | - | - | - | - | - | - | 0.95% | 0.99% | 0.94% | 0.72% | 0.84% | 1.01% | 0.99% | 0.83% | 0.98% | 1.00% | 1.05% | 1.27% | 0.86% | 0.99% | 1.07% | 0.48% | 0.86% | 0.99% | 0.87% | 0.75% | 1.00% | 2.72% |
Harvard Bioscience's average Quarter SG&A projection for Mar 24 is $18.89M, based on 1 Wall Street analysts, with a range of $15.11M to $22.67M. The forecast indicates a 64.20% rise compared to HBIO last annual SG&A of $11.51M (Dec 23).
Harvard Bioscience EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 18 |
| EPS | - | - | - | - | - | - | - | - | $-0.04 | $-0.03 | $-0.02 | $0.01 | $-0.04 | $-0.08 | $0.06 | $-0.17 | $0.02 | $-0.00 | $-0.01 | $-0.02 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $0.01 | $-0.07 | $-0.01 | $-0.06 | $-0.11 | $-0.03 |
| Avg Forecast | $0.04 | $0.01 | $0.03 | $0.01 | $0.04 | $0.01 | $0.05 | $0.04 | $0.05 | $0.04 | $0.06 | $0.05 | $0.03 | $0.07 | $0.06 | $0.04 | $0.10 | $0.05 | $0.05 | $0.03 | $0.08 | $0.04 | $-0.01 | $0.03 | $0.09 | $0.06 | $0.04 | $0.03 | $0.03 | $0.01 |
| High Forecast | $0.05 | $0.02 | $0.03 | $0.01 | $0.05 | $0.02 | $0.06 | $0.04 | $0.06 | $0.05 | $0.07 | $0.06 | $0.04 | $0.07 | $0.06 | $0.04 | $0.10 | $0.05 | $0.05 | $0.03 | $0.08 | $0.04 | $-0.01 | $0.03 | $0.09 | $0.06 | $0.04 | $0.03 | $0.04 | $0.01 |
| Low Forecast | $0.04 | $0.01 | $0.02 | - | $0.04 | $0.01 | $0.04 | $0.04 | $0.04 | $0.03 | $0.05 | $0.04 | $0.03 | $0.07 | $0.06 | $0.04 | $0.10 | $0.05 | $0.05 | $0.03 | $0.08 | $0.04 | $-0.01 | $0.03 | $0.09 | $0.06 | $0.04 | $0.03 | $0.02 | $0.01 |
| Surprise % | - | - | - | - | - | - | - | - | -0.86% | -0.72% | -0.39% | 0.20% | -1.19% | -1.23% | 1.00% | -3.78% | 0.23% | -0.08% | -0.20% | -0.60% | -0.25% | -0.86% | 4.00% | -3.60% | 0.17% | -1.17% | -0.16% | -1.80% | -3.67% | -3.00% |
According to 1 Wall Street analysts, Harvard Bioscience's projected average Quarter EPS for Jun 23 is $0.06, with a low estimate of $0.05 and a high estimate of $0.07. This represents a 500.00% increase compared to HBIO previous annual EPS of $0.01 (Mar 23).
Harvard Bioscience Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HBIO | Harvard Bioscience | $2.29 | $7.00 | 205.68% | Buy |
| AKYA | Akoya Biosciences | $3.13 | $7.90 | 152.40% | Buy |
| ANGO | AngioDynamics | $6.85 | $15.00 | 118.98% | Buy |
| KRMD | KORU Medical Systems | $3.08 | $3.25 | 5.52% | Buy |
| ICUI | ICU Medical | $171.96 | $172.00 | 0.02% | Buy |
| MMSI | Merit Medical Systems | $101.20 | $100.78 | -0.42% | Buy |
| LMAT | LeMaitre Vascular | $101.52 | $85.25 | -16.03% | Buy |